Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 28, 2012

Janssen Buys CorImmun for Clinical-Stage Heart Failure Drug

  • Janssen Cilag has bought German biotherapeutics firm CorImmun, to acquire the latter’s small cyclic peptide candidate COR-1. The acquisition deal includes an up-front payment and a future clinical milestone. COR-1 is in early clinical development for the potential treatment of heart failure. The peptide is designed to improve heart function by blocking autoimmune β-1 adrenergic receptor-stimulating antibodies.

    "COR-1 is an early-stage development compound with a novel mechanism for treating heart failure that has the potential to improve heart function by suppressing antibodies that can exacerbate this condition," remarks Peter M. DiBattiste, M.D., global therapuetic area head for cardiovascular disease and metabolism and Janssen Resaerch and Development. 

    CorImmun was established as a spin-out from the universities of Wuerzburg and of Tuebingen, and is focused on developing drugs for treating heart failure and atherosclerosis. The company has previously completed a clinical trial with the platelet adhesion inhibitor, ravacept/PR-15 (soluble dimeric glycoprotein VI-Fc fusion protein), in healthy volunteers. 



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »